Analyzing DNA to understand childhood cancers
Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia
NA · University Hospital, Montpellier · NCT04471961
This study is trying to understand the genetic causes of childhood cancers by looking at the DNA of kids with cancer and their parents to find clues that could help with treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Montpellier (other) |
| Locations | 1 site (Montpellier, Occitanie) |
| Trial ID | NCT04471961 on ClinicalTrials.gov |
What this trial studies
This study focuses on the genetic analysis of pediatric tumors by performing trio-based whole exome sequencing on children diagnosed with cancer and their parents. It aims to identify genetic predispositions and potential therapeutic targets in a multicentric approach involving multiple hospitals. By analyzing both tumor and germline DNA, the study seeks to enhance understanding of the genetic factors contributing to childhood neoplasia. The research will include 40 unselected cases of malignant tumors in children aged 0 to 17 years.
Who should consider this trial
Good fit: Ideal candidates include children aged 0 to 17 years diagnosed with solid or hematological malignancies, along with their biological parents.
Not a fit: Patients whose parents are under legal guardianship or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of genetic predispositions in childhood cancers, potentially guiding targeted therapies.
How similar studies have performed: Other studies utilizing genetic sequencing in pediatric oncology have shown promise, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patient has a solid or haematological malignancy, either familial forms or isolated cases diagnosed between the ages of 0 and 17 years. * The minor patient and both biological parents are available to participate in the study OR * The adult patient and one or both parents are available to participate in the study. * The patient's parents must have given their free and informed consent and signed the consent for the minor's participation in the study. * The patient's parent(s) must have given free and informed consent and the patient of legal age must have signed the consent for participation in the study. * The patient must be affiliated or beneficiary of a Frrench social security scheme. Exclusion Criteria: * The patient's parents are under guardianship or trusteeship or under legal protection Yes No * Failure to obtain written informed consent from parents (for themselves and their minor child) after a period of reflection Yes No * No affiliation to or beneficiary of a French social security scheme (for biological parents and the patient)
Where this trial is running
Montpellier, Occitanie
- CHU Montpellier — Montpellier, Occitanie, France (RECRUITING)
Study contacts
- Principal investigator: Pascal Pujol, PU-PH — Montpellier University Hospital
- Study coordinator: Pascal Pujol, PU-PH
- Email: p-pujol@chu-montpellier.fr
- Phone: +33 4 67 33 58 75
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pediatric Tumor, Familial Cancer, Solid Tumor, Childhood, Hematological Tumor, Pediatric oncology, Exome based trio, Cancer predisposition gene, Target therapies